Elan shareholders mull the unravelling of a business
How the Irish biotech firm got to this point and how the EGM may play out
How the Irish biotech firm got to this point and how the EGM may play out
Review of proxies suggests stalemate after four-month battle for control of company
Court move means bid will not lapse pending full hearing even if shareholders back certain resolutions
Fate of $6.7bn offer will be decided by shareholders at extraordinary general meeting on Monday
Pharmaceutical firm continues to urge shareholders to reject Royalty Pharma offer on grounds it is “grossly inadequate”
If all transactions are approved, Elan will have spent $3.3bn on M&A, share buybacks and bond redemptions
Crosswords & puzzles to keep you challenged and entertained
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices